<DOC>
	<DOCNO>NCT02104141</DOCNO>
	<brief_summary>The purpose combination retrospective prospective post market study examine short term safety efficacy ROI-A® interbody fusion device VerteBRIDGE® plat treat single two-level degenerative disc disease L2 S1 , focus fusion rate patient outcome .</brief_summary>
	<brief_title>Retrospective/Prospective Data Collection LDR ROIA Interbody Fusion Device With VerteBRIDGE Plating</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subjects must degenerative disc disease ( DDD ) lumbar spine L2 S1 Subjects may Grade 1 spondylolisthesis involve level ( ) Subject must ROIA® device one level two contiguous level L2 S1 Subject minimum 6 month nonsurgical treatment prior receive ROIA® device Subject may NO MORE THAN two previous nonfusion surgery lumbar spine level ROIA® Subject must least 21 year age time surgery Subject must willing sign informed consent document return 12 month visit Subject Grade 1 spondylolisthesis operate level Subject prisoner . Subject pregnant time surgery . Subject active infection sepsis time surgery .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DDD</keyword>
	<keyword>lumbar spine</keyword>
	<keyword>fusion rate</keyword>
	<keyword>degenerative disc disease</keyword>
</DOC>